2022 Fiscal Year Annual Research Report
The research of targeting tumor-associated macrophages, a new combination therapy strategy by macrophage polarization and immune checkpoint blockade
| Project/Area Number |
21K15586
|
|---|
| Research Institution | National Center for Child Health and Development |
|---|
Principal Investigator |
Hu Xin 国立研究開発法人国立成育医療研究センター, 移植免疫研究室, 研究員 (40868965)
|
|---|
| Project Period (FY) |
2021-04-01 – 2023-03-31
|
| Keywords | CD11b+ cells / β-glucan / PD-L1 / tumor microenvironment |
|---|
| Outline of Annual Research Achievements |
We focused on the efficacy of β-glucan anti-tumor therapy combined with anti-PD-L1 mAb treatment, and the mechanism of their synergistic effects could be fully verified. In our mouse melanoma model, treatment with a PD-L1 blocking antibody with β-glucan synergized tumor regression. After treatment with β-glucan and anti-PD-L1 mAb antibody, tumor infiltrating leukocyte (TILs) not only showed a competent T cell function and CTL population but also showed enhanced tumor-recruited CD11b+ cell activity. This effect was also verified in the peritoneal exudate CD11b+ cells of tumor-bearing mice.
|
Research Products
(5 results)
